Jean Deleage Net Worth

The estimated Net Worth of Jean Deleage is at least 17.2 百万$ dollars as of 26 July 2005. Jean Deleage owns over 171,997 units of Rigel Pharmaceuticals stock worth over 150,504$ and over the last 21 years Jean sold RIGL stock worth over 17,028,082$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Jean Deleage RIGL stock SEC Form 4 insiders trading

Jean has made over 9 trades of the Rigel Pharmaceuticals stock since 2004, according to the Form 4 filled with the SEC. Most recently Jean sold 114,239 units of RIGL stock worth 723,133$ on 1 December 2006.

The largest trade Jean's ever made was selling 177,600 units of Rigel Pharmaceuticals stock on 21 October 2004 worth over 4,448,880$. On average, Jean trades about 38,900 units every 38 days since 2003. As of 26 July 2005 Jean still owns at least 11,604 units of Rigel Pharmaceuticals stock.

You can see the complete history of Jean Deleage stock trades at the bottom of the page.

What's Jean Deleage's mailing address?

Jean's mailing address filed with the SEC is ONE EMBARCADERO CENTER SUITE 450, , SAN FRANCISCO, CA, 94111.

Insiders trading at Rigel Pharmaceuticals

Over the last 21 years, insiders at Rigel Pharmaceuticals have traded over 170,041,384$ worth of Rigel Pharmaceuticals stock and bought 2,068,700 units worth 7,281,949$ . The most active insiders traders include Partners L P/Ilbiotechnolog...、Ansbert Gadicke、Partners L P/Ilbiotechnolog.... On average, Rigel Pharmaceuticals executives and independent directors trade stock every 46 days with the average trade being worth of 961,207$. The most recent stock trade was executed by David A Santos on 2 February 2024, trading 14,519 units of RIGL stock currently worth 16,552$.

What does Rigel Pharmaceuticals do?

rigel pharmaceuticals, inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases.

Complete history of Jean Deleage stock trades at Cyclacel Pharmaceuticals Inc、Rigel Pharmaceuticals

Rigel Pharmaceuticals executives and stock owners

Rigel Pharmaceuticals executives and other stock owners filed with the SEC include:

• David A. Santos,
  Exec. VP & Chief Commercial Officer
• Raul R. Rodriguez,
  Pres, CEO & Director
• Dolly A. Vance,
  Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec.
• Dr. Wolfgang Dummer M.D., Ph.D.,
  Exec. VP & Chief Medical Officer
• Dean L. Schorno CPA,
  Exec. VP & CFO
• Julie Patel,
  Sr. VP of HR
• Tarek Sallam,
  VP of Marketing
• Dr. Esteban S. Masuda,
  Exec. VP of Research
• Joseph Lasaga,
  Sr. VP of Corp. Devel.
• Gary A Lyons,
  
• Brian L. Kotzin,
  
• Jane Wasman,
  
• Kamil Ali Jackson,
  
• Donald G Payan,
  Executive V.P. and CSO
• Peter S Ringrose,
  Director
• Keith Katkin,
  Director
• Ryan D Maynard,
  VP Finance, Acting CFO
• Esteban Masuda,
  Sr. VP Research
• Walter H Moos,
  
• Bradford S Goodwin,
  Director
• Stephen A Sherwin,
  Director
• Eldon C. Iii Mayer,
  EVP & Chief Commercial Officer
• James H Welch,
  VP, CFO and Corp Secretary
• Alan D Frazier,
  Director
• Elliot B Grossbard,
  Sr VP of Med Development
• Anthony Gregg Lapointe,
  
• Nelson Cabatuan,
  VP,Finance & Princ.Acctg. Off.
• Stacy Markel,
  EVP Human Resources
• Joseph Lasaga,
  Sr.VP Bus.Dev.Alliance Mgmt.
• Anne Marie Duliege,
  EVP & Chief Medical Officer
• Partners Ii Incalta Biophar...,
  
• Nicholas J Iii Simon,
  Director
• Bioventures Iii Qp Lpmpm Bi...,
  
• Lukegadicke Ansbert Evnin,
  
• Dennis Henner,
  Director
• Jeanalta Partnersalta Calif...,
  
• Nicholas Galakatos,
  10% owner
• Michael Steinmetz,
  10% owner
• Partners Ii Incalta Biophar...,
  
• Ansbert Gadicke,
  10% owner
• Luke Evnin,
  10% owner
• Bioequities Master Fund Lpm...,
  
• Healthcare Iv Lpfhm Iv Lpfh...,
  
• Lisa Rojkjaer,
  EVP, Chief Medical Officer
• James M Gower,
  CEO and Chairman of the Board
• Partners L P/Ilbiotechnolog...,
  
• Partners L P/Ilbiotechnolog...,
  
• Hollings Renton,
  Director
• James Edeerfield Capital Lp...,
  
• James Edeerfield Capital Lp...,
  
• Jean Deleage,
  Director
• Robin D G Cooper,
  Sr. V.P. Pharmaceutical Scs.
• David A Santos,
  EVP, Chief Commercial Officer
• Wolfgang Dummer,
  EVP & CMO
• Alison L. Hannah,
  
• Dean L Schorno,
  EVP & Chief Financial Officer
• Dolly Vance,
  EVP Corp. Affairs, G.C., Sect.
• Raymond J. Furey,
  EVP, GC, CCO & Corp Sec